Submissions from 2017
The Changing Role of Whole-Brain Radiotherapy: Demise or Time for Selective Usage?, Minesh Mehta
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases, Minesh Mehta
The role of radiation in treating glioblastoma: here to stay, Minesh Mehta
Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer, Minesh Mehta and Michael Chuong
Radiation Therapy for Liver Tumors: The State-of-the-art, Miguel Perez and Michael Chuong
Submissions from 2016
HPV-Associated Oropharyngeal Cancer: Changing Treatment Paradigm & Prognosis, Andre Abitbol
An overview of modern proton therapy, Minesh Mehta
Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer, Minesh Mehta
Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review, Minesh Mehta
Clinical ramifications of "genomic staging" of low-grade gliomas, Minesh Mehta
International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties, Minesh Mehta
Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study, Minesh Mehta
Reply to M.C. Chamberlain, Minesh Mehta
Stereotactic Radiosurgery for Treatment of Brain Metastases, Minesh Mehta
Submissions from 2014
Predictors of radiotherapy-related GI toxicity from anal cancer DP-IMRT: Secondary analysis of RTOG 0529, Andre Abitbol
Submissions from 2012
Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer, Alan Lewin, Robert Derhagopian, Andre Abitbol, D Jay Wieczorek, Vivek Mishra, and Lourdes Moreno
Submissions from 2007
Treatment of early non-small cell lung cancer, stage IA, by image-guided robotic stereotactic radioablation--CyberKnife, William Brown, Alan Lewin, and Andre Abitbol
Submissions from 2005
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol, Andre Abitbol, Alan Lewin, and Michael Troner
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma, Andre Abitbol, Alan Lewin, and Michael Troner
Submissions from 2002
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol, Andre Abitbol, Alan Lewin, Michael Troner, and Maria-Amelia Rodrigues
Submissions from 1996
Management of stage I-B, II-A, and II-B carcinoma of the cervix with high-dose-rate brachytherapy: initial results of an institutional clinical trial, Andre Abitbol and Alan Lewin
Submissions from 1993
Submissions from 1992
Stereotactic radiosurgery: dose-volume analysis of linear accelerator techniques, Christopher Serago, Alan Lewin, Andre Abitbol, Sergio Gonzalez-Arias, and Victor Marcial-Vega
Submissions from 1991
Scattering effects on the dosimetry of iridium-192, Christopher Serago, Andre Abitbol, Alan Lewin, and Victor Marcial-Vega
Stereotactic target point verification of an X ray and CT localizer, Christopher Serago, Alan Lewin, Sergio Gonzalez-Arias, and Andre Abitbol
Improved linac dose distributions for radiosurgery with elliptically shaped fields, Christopher Serago, Alan Lewin, Sergio Gonzalez-Arias, Andre Abitbol, and Victor Marcial-Vega